Cargando…

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor malignancies, leading to expression of an oncogenic TrkA fusion protein. Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farago, Anna F., Le, Long P., Zheng, Zongli, Muzikansky, Alona, Drilon, Alexander, Patel, Manish, Bauer, Todd M., Liu, Stephen V., Ou, Sai-Hong I., Jackman, David, Costa, Daniel B., Multani, Pratik S., Li, Gary G., Hornby, Zachary, Chow-Maneval, Edna, Luo, David, Lim, Jonathan E., Iafrate, Anthony J., Shaw, Alice T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748/ https://www.ncbi.nlm.nih.gov/pubmed/26565381 http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0

Ejemplares similares

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion
por: Liu, Stephen V., et al.
Publicado: (2017)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Alvarez-Breckenridge, Christopher, et al.
Publicado: (2017)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
por: Dziadziuszko, Rafal, et al.
Publicado: (2022)

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
por: Paz-Ares, L., et al.
Publicado: (2021)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
por: Dziadziuszko, Rafal, et al.
Publicado: (2021)

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer
por: Vaishnavi, A., et al.
Publicado: (2013)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

TMP3-NTRK1 rearranged uterine sarcoma: A case report
por: Boyle, William, et al.
Publicado: (2020)

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)

Imaging findings of NTRK‑rearranged spindle cell neoplasms: A case series
por: Kobayashi, Hiroshi, et al.
Publicado: (2023)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o9magmehosbvql5nbd8a7fudsa